



INTEGRATED
DIAGNOSTICS
HOLDINGS

IDH Results Presentation

June 2023



Table of Contents

- IDH At a Glance
- Q1 2023 Results Overview
- Key Investment Highlights

Our Market

Our Business Model

Financial Position and Performance


Growth Strategies

Governance



Who We Are (I/II)

Integrated Diagnostics Holding is a leading, fully-integrated provider of high-quality medical diagnostic services with a footprint spanning Egypt, Jordan, Nigeria, Sudan, and Saudi Arabia

An integrated diagnostics provider...



...with a suite of internationally-accredited, market-leading brands



Who We Are (II/II)

The Company's reach, scale, and service quality are unmatched across its markets of operation



Track Record

+40 years

First lab established in 1979



Accreditations

Sole CAP & ACR

Accredited lab and scan
in Africa



Patients

c.10 MN

Per year



Test Portfolio

+3,000

Tests



Tests

c.30 MN

Per year



Dual-listing

LSE in 2015 | EGX in 2021



Market Reach

Over **576** Branches


As at 31 March 2023



Sustainable Growth

20%

Revenue CAGR 2015-22



Our Service Segments

IDH's pathology offering currently contributes the lion share of revenue and patients. The Company's radiology services are quickly gaining momentum with their contribution to IDH's top-line doubling in the last twelve months

Pathology – 94% of Revenues¹

Through IDH's brands, the Group offers over 2,000 internationally accredited pathology tests ranging from basic blood glucose tests for diabetes to advanced molecular testing for genetic disorders.

558

Pathology
branches

1979

Year
launched

c. **10**mn

Patients served
each year

c. **30**mn

Tests performed
each year

Competitive Strengths



Track
Record



Reach and
scale across
attractive
markets



Visibility and
Reputation



Scalable
Business
Model

Radiology – 6% of Revenues^{1,2}

IDH offers a vast array of radiology services through Al Borg Scan in Egypt and Echo-Lab in Nigeria. Al Borg Scan is also the **sole radiology provider in Africa boasting the prestigious American College of Radiology (ACR) accreditation**, a testament to the high-quality services delivered by the venture.

18

Radiology
branches

2018

Year
launched

c. **948**k

Patients served
since inception

c. **1.5**mn

Scans conducted
since inception

Competitive Strengths and Strategic Advantages



Established
platform to
build on



High-fragment
and fast-
growing market



Diversify and
Grow Revenue
Streams



Deliver on one-
stop-shop
vision





An integrated offering catering to patients' evolving needs

¹ Share of IDH Q1 2023 consolidated revenue.

² Radiology revenues are calculated as Echo-Lab (IDH's Nigerian subsidiary) revenues plus Al-Borg Scan revenues (Egypt's radiology business).

Our Geographies

IDH currently operates the largest branch network amongst private providers in Egypt and boasts an established presence in four key markets in the Middle East and Africa

Egypt		Jordan		Nigeria		Sudan	
							
1979	520	2011	26	2018	12	2011	18
First began operations	Branches (51% in Cairo Region)	Acquisition of Biolab	Branches	Acquisition of Echo-Lab	Branches	Acquisition of Ultra Lab	Branches
#1	80%	#1	16%	Top 5	3%	#1	1%
Market Ranking ¹ (#1 in Corporate Insurance Sector)	Share of consolidated revenues in Q1 2023	Market Ranking ¹	Share of consolidated revenues in Q1 2023	Market Ranking	Share of consolidated revenues in Q1 2023	Market Ranking ¹	Share of consolidated revenues in Q1 2023
1.8 mn	7.3 mn	92 k	582 k	35 k	72 k	11 k	33 k
Patients served in Q1 2023	Tests performed in Q1 2023	Patients served in Q1 2023	Tests performed in Q1 2023	Patients served in Q1 2023	Tests performed in Q1 2023	Patients served in Q1 2023	Tests performed in Q1 2023

¹ Market ranking amongst private players in each respective country.

Our Patients

IDH serves two principal types of patients: contract and walk-in

Around 70% of total revenue generated across the two segments is paid in cash

Contract Patients¹

IDH's **contract clients include institutions who enter into one-year renewable contracts** at agreed rates per-test and on a per-client basis. Around 40% of the revenue generated by the segment is paid in cash.


IDH's corporate clients roster currently features institutions such as:

- Unions
- Syndicates
- Private and public insurance companies
- Banks and corporations
- Public institutions
- Government insurance


Walk-In Patients

IDH's walk-in clients, also referred to as "self-payers", **pay out of pocket** for diagnostic tests and other services.

Contribution to IDH Revenues (Q1 2023)



Patient Split by Segment (Q1 2023)



¹ Testing prices at the contract segment are generally lower than those of the walk-in segment and are not pre-set as with walk-in testing

IDH Post Covid-19 : A new chapter (I/II)

During the Covid-19 era, IDH successfully transformed its business, expanding its service offering and delivery capabilities, and setting the foundation for a new chapter of sustainable growth, testament to its business agility and resilience



Test Offering and Delivery

Conventional Business Back to Pre-Covid Levels

+78%

Growth in conventional test¹ revenue vs Q1 2019

Ramped up House Call Services

16%

House call contribution to Egypt revenues in Q1 2023 (exceeding pre-pandemic averages of 10-11%)

Frontline Role in Fight Against Covid-19

9.0 mn

Covid tests performed in Egypt and Jordan (2020-2022)

AI-Borg Scan Expansion

6

Operational Branches as at 31 March 2023 (fastest growing radiology brand in Egypt)



Reach and Visibility

Ramped Up House Call Capacity

up to 5k

House call visits per day, with over 10k calls answered daily

Growing Physical Presence

+56

New branches opened during the last 12-month period

New Patient Segments

c. 5 mn

New patients acquired during Covid-19-pandemic (2020-2022)

Largest Private Provider in Egypt

576

Operational Branches as at 31 March 2023 (520 branches in Egypt)



Agility

Rapid Service Offering Adaptation

#1

in PCR testing in Egypt and first to offer QR codes

#1

leading PCR testing provider in Jordan

#1

for house call volumes in Egypt

Ample Capacity for Growth

5-7 yrs.

Average contract tenors for equipment

40%

Spare processing capacity in Mega Lab

A patient-centric business geared for long-term, sustainable growth

¹ Convention tests refers to IDH's service offering excluding all Covid-19-related testing performed during the period.

IDH Post Covid-19: A new chapter (II/II)

During the Covid-19 era, IDH successfully transformed its business, expanding its service offering and delivery capabilities, and setting the foundation for a new chapter of sustainable growth, testament to its business agility and resilience



Improved Efficiency

Decreased Turnaround Times and Improved Patient Satisfaction

over 80%

Net Promoter Score (NPS)

max 24hr

Turn-around time

Expanded Digital Capabilities

over 5k Chatbot conv/day

Diversifying patient touch-points

Convenient Payments

Leveraging expanded digital presence



Long-term Relationships

Revamped Loyalty Programme

In partnership with leading loyalty solutions provider to retain existing/new patients acquired in 2022

Expanded Cross-selling Capabilities

Monitoring patient records and disease cycles to provide tailored services and increase cross-selling

Marketing Strategy

Visibility bolstered by additional marketing efforts throughout the year including launch of new IDH branded cars as well as greater social media presence

A patient-centric business geared for long-term, sustainable growth

1 Convention tests refers to IDH's service offering excluding all Covid-19-related testing performed during the period.


Q1 2023 Results Overview




A Turbulent Operating Environment

IDH continues to post impressive financial and operational results despite difficult economic circumstances across its markets


A weakening Egyptian pound | EGP:USD




Record-high inflation eating at patients' purchasing power



Nigeria continues to face accelerating inflation particularly impacted by rising fuel prices



Ongoing tension in Sudan exacerbating an already difficult macroeconomic environment with record-high inflation



Results Snapshot

IDH reports sustained growth in traditional offering showcasing the fundamental strength and potential of the business

EGP **915** mn

Revenue¹ in Q1 2023

▲ 43% y-o-y conventional revenue growth
Total revenues declined 22% y-o-y
(Covid-19-related testing constituted 46% of consolidated revenues in Q1 2022)

EGP **325** mn

Gross Profit in Q1 2023

▼ 39% y-o-y / 35% margin

EGP **227** mn

EBITDA² in Q1 2023

▼ 51% y-o-y / 25% margin

EGP **168** mn

Net Profit in Q1 2023

▼ 46% y-o-y / 18% margin

8.0 mn

Tests completed in Q1 2023

▲ 12% y-o-y conventional test volume growth
(▼ 4% y-o-y in consolidated terms)

1.9 mn

Patients served in Q1 2023

▼ 27% y-o-y

EGP **114**

Average revenue per test in Q1 2023


▲ 27% y-o-y ex-Covid-19-related** testing
(▼ 19% y-o-y in consolidated terms)

576





Operational branch labs as at 31 Mar. 2023

▲ 56 branches vs. 31 Mar. 2022
(24 branches rolled out during Q1 2023)

Revenue Drivers Q1 2023



Revenue Breakup Q1 2023



¹ Starting Q1 2023, IDH has opted to stop reporting on its Covid-19-related revenues and test volumes due to their material insignificance to the consolidated figures and to Egypt's and Jordan's country-level results for the quarter. In the comparable period of last year (Q1 2022) IDH had recorded EGP 540 million in Covid-19-related revenues and had performed 1.3 million Covid-19-related tests. As such, all figures used throughout this presentation are IFRS-compliant.

² EBITDA is calculated as operating profit plus depreciation and amortization.

³ Radiology revenues are calculated as Echo-Lab (IDH's Nigerian subsidiary) revenues plus Al-Borg Scan revenues.


Sustainable Growth Despite Seasonality – Quarterly

IDH's conventional business stood 78% above pre-pandemic levels in Q1 2023 showcasing the strength and potential of its underlying business

Conventional revenues continue growing solidly supported by higher volumes and increased pricing

(Revenue | EGP mn)


Growth in conventional business: **+78%**



Conventional revenue per test currently stands 50% above levels recorded in Q1 2019

(Revenue per Test | EGP)


+50% Growth in Conventional Revenue per Test



With conventional tests growing at pre-pandemic pace


(Test Volumes | mn)

+18% Growth in Conventional Test Volumes



And overall patient volumes continuing to normalise to pre-pandemic figures and tests per patient reach all time highs

(Patient Volumes | mn)




Continued Growth at Egypt's Radiology Venture

Al Borg Scan, Egypt's radiology venture, continues posting impressive top-line growth on the back of increased test volumes and higher average revenue per test


Sustained growth in radiology revenues...

(Revenue, % of Egypt Revenues | EGP mn, %)




...on the back of increased test volumes...

(Scans performed | '000)




...higher patient traffic...

(Patients served | '000)



...and a steady rise in average revenue per test


(Average revenue per test | EGP)




Profitability Overview

Lower profitability down the income statement largely reflects increases in salary and wage expenses, increases in IDH's marketing expenses to support the rollout of new branches, and increased inflationary pressures as a result of a weakened EGP

Despite inflationary pressures, as a percentage of sales total raw materials have remains relatively stable



Increases in salaries and wages as a percentage of sales showcase IDH's higher than usual compensation increases in light of inflationary pressures in its home market, Egypt



IDH has also optimized spending allocations targeting areas set to drive long term growth for the Group


14%

Increase in direct salaries and wages as part of **staff retention strategy**. This will ensure IDH remains an **employer of choice** across its markets and build **staff long-term loyalty**.

43%


Year-on-year rise in marketing expenses mainly to support **Al-Borg Scan's ramp up** and the newly rolled out branches. Growing IDH's direct patient touch points (branches) and its radiology business are two key pillars of the company's long-term **sustainable growth strategy**.

Lower margins at all levels
(GP, EBITDA, and NP Margin | %)



Non-Recurring Items in Q1-2023


IDH recorded increased profitability at both the EBITDA and net profit levels compared to reported figures due to non-recurring items




* For more information on these expenses, kindly refer to IDH's 1H 2023 earnings release

Revenue – EBITDA Bridge

Q1 2023 IDH Revenue - EBITDA Bridge | M-EGP




Q1 2022 IDH Revenue - EBITDA Bridge | M-EGP




EBITDA – Net Profit Bridge


Q1 2023 IDH Revenue - EBITDA Bridge | M-EGP



Earnings Before Tax | M-EGP









Income & Deferred Tax, Effective Tax Rate | M-EGP, %



Solid Financial Position


The Group maintains a robust financial position, with a liquid balance sheet thanks to a strong cash generation profile allowing for consistent dividend payouts



*The net cash/(Debt) balance is calculated as cash and cash equivalent balances less interest-bearing debt (medium term loans), finance lease and right-of-use liabilities.

Q1 2023 Capital Expenditure

IDH CAPEX recorded **EGP 217.4m in Q1 FY23**, including both, core recurring CAPEX items and non-core non-recurring items. Such figure represented **23.7% of Q1 FY23 total net sales**.



The **core CAPEX** amounting to **EGP 42.0m (19%)** was mainly allocated to Renovation, new branches, warehouses and IDH HQ. Accounting for such items only, **normalized CAPEX** would have recorded **4.6% only** from Q1 FY23 total **net sales**.

Non-recurring CAPEX amounting to **EGP 175.3mn (81%)** resulted from Currency translation from foreign subsidiaries in addition to Al Borg Scan expansion.

% of Total CAPEX



Egypt ————— **EGP 75.7mn**
34.8%



Nigeria ————— **EGP 43.9mn**
20.2%




Jorda ————— **EGP 97.3mn**
44.8%




Sudan ————— **EGP 464k**
0.2%

Fixed Gross Assets Bridge

IDH Fixed Gross Assets Bridge by Account | M-EGP



IDH Fixed Gross Assets Bridge by Region | M-EGP



Segment Performance

Both IDH's contract and walk-in segments witnessed significant conventional revenue growth in Q1 2023. Conventional revenue growth at IDH's contract segment was dual driven by increases in test volumes and average revenue per test, while walk-in segment revenues were entirely driven by increased average revenue per test.

	Walk-in Segment			Contract Segment			Total		
	1Q22	1Q23	Change	1Q22	1Q23	Change	1Q22	1Q23	Change
Revenue (EGP mn)	535	337	-37%	645	579	-10%	1,180	915	-22%
Conventional Revenue (EGP mn)	244	337	38%	396	579	46%	640	915	43%
Total Covid-19-related revenue (EGP mn)	291	-	-	250	-	-	540	-	-
Patients ('000)	971	422	-57%	1,678	1,517	-10%	2,649	1,939	-27%
% of Patients	37%	22%		63%	78%				
Revenue per Patient (EGP)	551	798	45%	385	381	-1%	446	472	6%
Tests ('000)	2,144	1,519	-29%	6,258	6,517	4%	8,402	8,036	-4%
% of Tests	26%	19%		74%	81%				
Conventional tests ('000)	1,530	1,519	-0.7%	5,618	6,517	16%	7,148	8,036	12%
Total Covid-19-related tests ('000)	614	-	-	641	-	-	1,254	-	-
Revenue per Test (EGP)	250	222	-11%	103	89	-14%	140	114	-19%
Conventional Revenue per Test (EGP)	160	222	39%	70	89	26%	90	114	27%
Test per Patient	2.2	3.6	63%	3.7	4.3	15%	3.2	4.1	31%

6.5 mn

Contract tests
in Q1 2023

▲ 16% y-o-y excluding
Covid-19-related* tests
▲ 4% y-o-y in
consolidated terms

EGP 89

Avg. revenue / contract test
in Q1 2023

▲ 26% y-o-y excluding
Covid-19-related* tests
▼ 14% y-o-y in
consolidated terms

EGP 579 mn

Contract revenues
in Q1 2023

▲ 46% y-o-y excluding
Covid-19-related* tests
▼ 10% y-o-y in
consolidated terms

1.5 mn

Walk-in tests
in Q1 2023

▼ 0.7% y-o-y excluding
Covid-19-related* tests
▼ 29% y-o-y in
consolidated terms

EGP 222

Avg. revenue / walk-in test
in Q1 2023

▲ 39% y-o-y excluding
Covid-19-related* tests
▼ 11% y-o-y in
consolidated terms

EGP 337 mn


Walk-in revenues
in Q1 2023

▲ 38% y-o-y excluding
Covid-19-related* tests
▼ 37% y-o-y in
consolidated terms


*Covid-19-related tests include both core Covid-19 tests (Polymerase Chain Reaction (PCR), Antigen, and Antibody) as well as other routine inflammatory and clotting markers including, but not limited to, Complete Blood Picture, Erythrocyte Sedimentation Rate (ESR), D-Dimer, Ferritin and C-reactive Protein (CRP), which the Company opted to include in the classification as "other Covid-19-related tests" due to the strong rise in demand for these tests witnessed following the outbreak of Covid-19.

Segment Performance


IDH's contract segment maintained its growth trend, remaining the major contributor to overall revenue and patient volumes in Q1 2023



Revenue Split




■ Walk-in ■ Corporate




■ Walk-in ■ Corporate

Patient Split




■ Walk-in ■ Corporate



■ Walk-in ■ Corporate

Regional Performance (I/II)

IDH witnessed strong results from its conventional business in Egypt and Jordan, with both its Nigerian and Sudanese operations recording solid results for the first quarter of 2023



Regional Performance (II/II)



Regional Performance: Local Currency



SDG = 0.0052 EGP, JOD = 43.863 EGP, and NGN = 0.0662 EGP


■ Total Covid-19-related Revenue

■ Conventional Revenue

Continued Growth at Echo-Lab (Nigeria)

IDH's Nigerian operations reported year-on-year revenue growth of 26% in NGN terms in Q1 2023. Top-line growth was supported by a 9% year-on-year increase in average revenue per test (in local currency terms) in part reflecting the rising demand for the generally higher-priced CT and MRI exams during the year.

Monthly Revenue April 2020 to March 2023 | NGN* million



* NGN/EGP @0.04 in Q1 2022 and @0.07 in Q1 2023 approximately

Continued Ramp up at Al Borg Scan


Robust revenue growth continued to be supported by higher test and patient volumes as the four new branches rolled out since September 2021 continue to ramp up. In August, Al-Borg Scan obtained ACR accreditation for its Nuclear Medicine and Ultrasound units.



Al Borg Scan offers a full range of radiology services, including but not limited to Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Ultrasound, X-ray and Mammograms.

EGP 28 MN	37%	20%	17%	14%
Q1 2023 revenues +65% vs Q1 2022 (4% of Egypt revenues)	Q1 2023 revenue contribution Mohandessin branch	Q1 2023 revenue contribution Merghany branch	Q1 2023 revenue contribution Faisal branch	Q1 2023 revenue contribution Shubra branch
11%	1%	31k	EGP 664	42k
Q1 2023 revenue contribution CBP branch	Q1 2023 revenue contribution Maadi branch	Q1 2023 patients +30% vs. Q1 2022	Q1 2023 avg. Revenue/test +21% vs. Q1 2022	Q1 2023 tests +37% vs. Q1 2022

Al Borg Scan Monthly Revenue (October 2018 to March 2023) | M-EGP




Sudan Financial Performance & Operational Status

Sudanese Conflict Updates

On April 15, 2023, violent conflict erupted between two rival groups in Sudan: the Sudanese Armed Forces (SAF) and the Rapid Support Forces (RSF). Fighting has happened primarily in urban centers, which is why civilian casualties have been so high: Over 400 civilians have died and more than 4,000 are injured.

IDH's two brand names, Ultra Lab and Al Mokhtabar-Sudan, have been dramatically affected, whereby out of 18 branches, **only 2 are still operating**, while the other 16 have been closed/destroyed.

Detailed Operational Overview as at 31 May 2023



11

Ultra Lab branch network as at May 2023

7

Al Mokhtabar branch network as at May 2023

3

Cities covered by IDH's branch network in Sudan

145

Number of IDH staff members across IDH's 18 branches

Outlook and Strategies (I/II)

In IDH's home and largest market of Egypt, the Company's priorities for the remainder of the year remain unchanged



Pricing

Strategic price increases across entire service offering



Volumes

Patient retention is a priority in turbulent times



Raw Materials

Leverage strong supplier relations to control kit price inflation



Cost Optimization

Rationalise major costs while maintaining service levels



Employees

Retain staff through competitive compensation packages

Egypt - Capitalizing on competitive pricing, supplier relationships and inelastic demand

Volume Growth

The Group has focused on sustained volume growth aided by strategically introduced price hikes at both its walk-in and contract segments as well as at the radiology segment

Double radiology contribution

capitalizing on growing momentum and new branch ramp up/rollouts

Strong supplier relations

The Group has recently renegotiated its test kit contracts at favourable terms

+33%

The Group's efforts have paid off with the country delivering double-digit conventional revenue growth in Q1 2023

Outlook and Strategies (II/II)

Throughout the quarter, IDH continued to deliver short-term growth in line with its targets while progressing on its longer-term strategy

Jordan - Double-digit growth in LCU terms driven by solid volumes

New Branches

Completed ramp-up of new branches to drive volume growth

Test volume growth

In line with pre-pandemic averages to sustain double-digit revenue expansion

Pre-pandemic
EBITDA margin

c. 17-18%

Rising contribution to IDH's total revenue in 2023 (in part due to translation differences)

Nigeria - Capital increase gives further fuel for growth

Double-digit

Revenue growth in FY 2023 supported by growing volumes and increasingly optimised test mix

Challenging operating environment

Currency depreciation, inflation, fuel price hikes set to weigh on profitability throughout FY 2023

Saudi Arabia - Penetrating a fifth, fast-growing and underserved market

January 2024

Inauguration of first branch

US\$ 19.7 mn

Estimated investment cost (SAR 73.7 mn)

Attractive diagnostic market growth profile

One of the fastest growing in the Middle East and Africa (MEA) over the coming six years

FY 2023 Consolidated Guidance

30%

Year-on-year conventional revenue growth in FY 2023

Profitability

Full-year profitability is set to be supported by strategic price increases, sustained volume recovery and cost optimization efforts but will be temporarily affected in the short-term (versus historical levels) by ongoing macroeconomic challenges and one-off expenses.

Investment Highlights



Investment Highlights

IDH is an attractive investment opportunity with compelling fundamentals, present in fast-growing, under-served markets



1

Operating in highly fragmented markets characterised by strong structural growth drivers and high barriers to entry



2

Deploys an asset-light business model that allows for quick, capital-efficient growth helping to strengthen IDH's brand equity and maintain its position as the number one private provider in Egypt and Jordan



3

Strong historical growth with attractive margins, an unlevered balance sheet, and strong cash generation ability allowing for consistently high dividend distribution



4

Allowing for capitalization on multiple future growth avenues



5

Supported by a world-class management and board of directors with robust governance frameworks



Fast-Growing, Underserved Markets



The background is a complex digital collage. A large DNA double helix runs diagonally from the bottom left towards the top right. In the center, a magnifying glass is positioned over a bar chart with blue and red bars. To the left of the magnifying glass, there is a cluster of hexagonal icons: a brain, a syringe, lungs, a kidney, and a pill. Above these hexagons is a large teal cross. To the right of the magnifying glass, there are more hexagons, including one with a heart and a pulse line. Below the magnifying glass, there is a chemical structure of a peptide: NC(=O)C(CS)C(=O)O. Another chemical structure, O=C(O)c1cccnc1, is located in the bottom right corner. The background is filled with various data points, numbers, and smaller icons, creating a high-tech, medical research atmosphere.


Favorable Industry Dynamics

IDH's home market of Egypt is underpinned by robust structural growth drivers

Operating in a still under-penetrated market

Healthcare expenditures-per-capita and lab tests-per-capita demonstrate the underpenetrated nature of the IDH's markets.


Lab tests per capita (2012)




Large Populations

At well over 100 million, Egypt is the third most populous country in Africa and by far the most populous country in the Middle East.

African Populations 2022 (in millions)



Middle Eastern Populations 2022 (in millions)



Top 5 African and Middle Eastern Country Populations

High Disease Burden

The Egyptian population is marked by a high incidence of lifestyle-related medical conditions, with obesity being a notable example given its high correlation with many life-threatening illnesses including cardiovascular disease, diabetes and cancer.

35%

Adult Egyptian population that is obese

10%

Egyptian children who are considerably overweight

28%

Heart disease, the leading cause of death, highly correlated with obesity



Heightened Health Consciousness

A growing consumer class is, however, becoming more health and wellness conscious.

Favorable Industry Dynamics

IDH's markets are characterised by high barriers to entry



Economies of Scale

IT-enabled platform, critical mass (higher margins), decades of know-how and cutting-edge equipment mitigate against new entrants



Accreditation of Facilities

Attracting patients requires accredited, high-quality testing capabilities



Brand & Reputation

Patients are loyal to brands with a long track record for safety and quality



Market Reach

Fragmented markets necessitate a far-reaching network of branches to serve population effectively





Key Stakeholder Relationships

Building a scalable platform requires strong relationships with all stakeholders – from key suppliers to the Ministry of Health

IDH is a Consumer-Facing Service Provider

The mechanics of healthcare markets in developing economies are markedly different from those in many Western healthcare industries




Scalable Business Model



Asset-light Business Model

IDH's "Hub, Spoke and Spike" business model enables the Company to organically expand its reach in highly-fragmented markets with underserved diagnostic services demand



Mega Lab: "Hub"

- The Mega Lab, the largest automated lab in Egypt, serves as IDH's diagnostic "Hub," equipped with the latest technology to provide a full suite of diagnostic tests.
- Significant cost synergies are realized on kits, logistics and quality control.

B Labs: "Spokes"

- The B Labs serve as "Spokes" that reduce traffic to the Mega Lab by processing routine test on site including chemistry, parasitology and hematology.
- B Labs are both large in size and higher in capacity than the C Labs.
- At 31 March 2023, there were eight B Labs in Egypt and 26 in Jordan.

C Labs: "Spikes"

- The C Labs are collection centers, conducting the most basic of tests.
- Because they require low capital to open, they enable IDH to expand its reach in highly-fragmented markets.
- Typical C Labs take an average of three months to set up.

Our Mega Lab

IDH's Mega Lab is the only CAP-accredited facility in Egypt, demonstrating the excellence of IDH's patient care and confidence in the laboratory's practices

Capabilities

- Mega Lab machines are **capable of conducting a wide range of tests**.
- Mega Lab is equipped with **state-of-the-art equipment from leading medical equipment suppliers**.
- New and esoteric test facilities at the Mega Lab **allow IDH to offer over 3,000 diagnostic tests**, helping to drive IDH's key test-per-patient metric.
- Solid **Lab Management System (LMS)** allows the **immediate disbursal of results through SMS**.

Capacity

- IDH's Mega Lab **doubled testing capacity to 30,000 tests per hour**.
- Capability for a broad range of tests provides IDH the ability to **plug and play for further expansion**.
- IDH's Mega Lab typically operates at 55% of its capacity leaving **ample room for further growth**.

Procurement

- Central procurement system ensures **coordinated purchasing across the Group**.
- IDH is able to negotiate **favourable kit prices** and procure additional equipment to enhance capacity.
- Centralised procurement model enables the company to **expand its operations in an efficient manner**.
- Thanks to its long-standing supplier relationships, IDH's **Mega Lab boasts the longest Siemens track** in the Middle East and Africa

Quality Control

- IDH's **Mega Lab is the only CAP-accredited facility in Egypt**, demonstrating the excellence of IDH's patient care.
- **IDH adheres to the highest quality standards**, with safety and testing procedures continuously enhanced.
- The centralization resulting from Mega Lab allows IDH to maintain a **tight oversight on quality**.

Key Figures

2015

Year of Establishment

100 k

Test per Day Workload

15

Operating Units in a 6-floor building

270

Employees

4,000 sqm

Total Area

24/7

Operating Hours

Key Supplier Relationships

IDH leverages its bargaining power with suppliers to maximize value in a business that is fundamentally about economies of scale. Combined with the long-tenure nature of its supplier contracts, this provides significant protection against short-term price fluctuations.

Dynamics of Supplier Relationships

IDH engages in reagent deals whereby the majority of its testing equipment is provided at no upfront payment as part of a wider agreement to purchase a minimum volume of kits from the equipment supplier.

These contracts typically have tenors ranging from 5 to 7 years, with the equipment substituted following the contract's renewal.

Laboratory test kits are purchased on contract with volume-linked pricing.

Significant volume and scale has also placed the Company in a favorable position to negotiate test kit prices, thus manage costs effectively, especially during recent challenging macroeconomic times.

Supplier relationships helped protect gross margins despite a >50% devaluation of the EGP after the November 2016 float and are continuing to safeguard the business' cost base during the ongoing EGP devaluation (down c. 97% from March 2022 to March 2023).

INTEGRATED DIAGNOSTICS HOLDINGS

biolab

Alborg
Laboratories

ECHO
LAB
RADIOLOGY &
LABORATORY
SERVICES

alborg
scan

المرکز
للأشعة
ULTRA LAB

al mokhtabar
مركز التحاليل

SIEMENS

Roche

sysmex

Abbott
A Promise for Life







SUPPLIERS

Strong Growth and Financial Position



Key Financial Performance Indicators





Since the Company's IPO on the LSE in 2015, IDH has delivered consistent top- and bottom-line growth supported by a steady increase in volumes and increasingly favourable pricing across the Group's service offering



* Adjusted EBITDA is calculated as EBITDA excluding one-off expenses incurred by the Group in FY 2021 and FY 2022.

Key Financial Performance Indicators (USD)


IDH has successfully delivered positive top- and bottom-line growth in USD terms since listing on the LSE despite several devaluations and a difficult operating environment



* Adjusted EBITDA is calculated as EBITDA excluding one-off expenses incurred by the Group in FY 2021 and FY 2022.


Regional Performance (I/II)

Across its footprint, the Company deploys tailored expansion strategies which enable it to continue driving growth irrespective of the prevailing macroeconomic environment






Regional Performance (II/II)

Across its footprint, the Company deploys tailored expansion strategies which enable it to continue driving growth irrespective of the prevailing macroeconomic environment



Growth Strategies



Future Growth Strategies

IDH's growth strategies rely on leveraging its competitive advantages to achieve four strategic goals

Expand Customer Reach

Beyond opening laboratories in new geographies, IDH is reaching out to new customers with focused tactical marketing activities as well as new customer services.

Expand Geographically

In addition to organic expansion, the Company continues to seek value-accretive acquisitions in African and Middle Eastern markets where its business model is well-suited to capitalise on similar healthcare and consumer trends and capture significant share of fragmented markets.

Increase Tests per Patient

While opening more branches will add both patients and tests, further diversifying the test portfolio in combination with compelling offerings of promotionally-priced test packages will drive the key financial metric of number of tests per patient.

Diversify into New Medical Services

The Group also looks to add diagnostic and medical services not currently provided on a large scale, believing its scale and experience position it well to take advantage of developing services opportunities that would raise the IDH profile to that of a "one-stop-shop" provider.

Expanding Customer Reach – Growing In Egypt

The Group enjoys ample growth room in Egypt thanks to its market leading position and extensive reach, attractive underlying fundamentals, and favourable regulatory environment

Reach and penetration

New growth opportunities in Egypt and other markets, coupled with IDH's market leading position, expanded product offering and patient base, increased service delivery capabilities, and growing visibility see the Company ideally positioned to continue **delivering robust growth in 2022 and beyond.**

48

New branch roll outs since 31 Mar. 2022

Expanded digital presence


New loyalty programmes (Dsquares)

Largest branch network in the country

Increased cross-selling capabilities

Solid Fundamentals

Forecasted GDP Growth¹



1.76%

Average annual population growth rate 2020-2025

62%

Proportion of undiagnosed diabetes² in adult Egyptian population (1 in 5 adults has diabetes)

35%

Adult Egyptian population that is obese

28%

Heart disease, the leading cause of death, highly correlated with obesity

Universal Healthcare Act

The Universal Health Insurance Law No.2 was introduced in 2018 to modernise the country's outdated health insurance system. To be completed in 2030, the new framework aims to extend coverage and access to high-quality healthcare and insurance to all of Egypt's population, in turn opening up important growth opportunities for the private sector.

5

Egyptian cities now covered by universal healthcare act

12

IDH accredited labs for uni. healthcare programme in Egypt

35%

Completion of Universal Insurance rollout

Private Sector

The Egyptian government is looking to incentivize private sector participation to aid in programme's success

¹ Statista April 2022, ² IDF Diabetes Atlas 2021

Diversifying Service Offering – Al Borg Scan Ramp-Up

IDH's radiology venture, Al Borg Scan, continues expanding its top line on the back of increased test volumes and average revenue per test

2018

Year of Establishment

6 branches

Covering Cairo from East to West

Fastest growing chain in Egypt

EGP **200** mn

Revenue

Since inception

349 k

Scans Performed

Since inception

269 k

Patients Served

Since inception

EGP **28** mn

Revenue in 1Q 2023

159% 2018-2022 CAGR

EGP **664**


Average Revenue per Test in 1Q 2023

▲ 21% y-o-y


c. EGP **550** mn

Total Investment to Date

Enjoying wide and expanding coverage across Greater Cairo



Leading to rapidly growing revenues since inception



Diversifying Service Offering – Al Borg Scan Expansion Updates

Al Borg Scan operates six branches, two of which were inaugurated in 2022. The Group also recently earned the prestigious ACR (American College of Radiology) accreditation for Al Borg Scan’s Nuclear Medicine and ultrasound units.



Al Borg Scan draws on Al Borg’s brand equity to position itself as a premium service provider offering the full range of imaging services using the latest technology and highly trained staff.



ACR Certified

Rationale

Leverage the strong relationship between the Al Borg brand and its millions of customers while capitalizing on favorable key market dynamics.

Leadership

The business is led by a group of the nation’s most prominent radiologists with a track record at Egypt’s leading hospitals and radiology centres.

International Accreditations

In 2022, Al-Borg Scan’s Nuclear Medicine and Ultrasound units obtained ACR accreditation, the first lab in Africa to earn the prestigious certificate

Near-Term Goals

Inaugurate one more branch in 2023 to take total to seven by year-end.

Alborg Scan Overview

Al Borg Scan offers a full range of radiology services, including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, x-ray and mammograms.

Technology Providers



Key Services



CT Scan



MRI



X-Ray




Mammography



Ultrasound



EMG



PET-CT



EEG



CT Scan



Stress ECG



Panorama and Cone Beam CT Imaging



DEXA









Anesthesia Services



Urodynamics

AI Borg Scan Maintains Growth Trajectory

IDH's Egyptian radiology venture, AI Borg Scan, continues expanding its top-line and expanding its contribution to Egypt revenues, driven by sustained increases in test volumes and higher revenue per test



House Call Services (Egypt and Jordan)

IDH's house call services, offered in both Egypt and Jordan, is becoming a primary contributor to top-line, averaging 15-20% compared to a pre-pandemic contribution of c.10%



Expands Reach

Expands IDH's customer base reaching new segments of the populations



Fee-Based

Services are offered at the same price as those performed at physical branches plus an additional fee to cover travel costs



Profitable

Tests performed as part of IDH's House Call offering have largely the same contribution margin as conventional tests performed at labs




Records for Cross-Selling

Once new patients are onboarded, their records are stored in IDH's system to provide tailored services and develop a long-term relationship


House call services witnessed rising demand during the Covid-19 pandemic

Up to **5,000**
Visits per Day

Up to **10,000**
Answered Calls per Day



Revenue
Contribution



c.4.8

Tests per Patient in FY22

952 k

House call Patients Served FY22

EGP 120

Revenue per Test in FY22

4.6 mn

House call Tests Performed FY22

Expanding Customer Reach – State-sponsored Initiatives

IDH's nationwide presence and strong brand equity position it well to benefit from state-sponsored campaigns to increase awareness of preventative healthcare with diagnostic testing

Duration

8 months

Nov '18 – Jun '19

Diagnostic Testing Targeting

50 mn

Citizens

Reach

Nationwide

Cost

Free for citizens



"100 Million Healthy Lives" campaign

The largest health campaign under the directive of the Egyptian President Abdel-Fattah El-Sisi, which aims to **eradicate hepatitis C across Egypt** as part of the administration's strategic 2020 plan.

The campaign also aims to **stymie the growth of chronic diseases** such as high blood pressure, diabetes and obesity, **by raising awareness on the importance of preventative healthcare with diagnostic testing.**

The campaign was launched in November 2018 and concluded in June 2019.

Revenue Generated

EGP 84 mn

Nov '18 – Jun '19

Tests Completed

4.4 mn

Nov '18 – Jun '19

Patients Served

409 K

Nov '18 – Jun '19

Average Revenue per Test

EGP 18

Expanding Customer Reach – IDH Awareness Campaigns

Parallel to state-sponsored initiatives, IDH also runs its own awareness campaigns focusing on specific diseases on a monthly basis and offering discounts on related testing

IDH's PCR Offers and Campaigns



Discounts on PCR testing for Covid-19



PCR testing for Covid-19 for people traveling

IDH Disease Awareness and Discount Campaigns



20% discounts on food poisoning tests



Campaign to increase awareness on the dangers of anemia during pregnancy

Diversifying Service Offering – New Investment in Wayak

IDH launches new subsidiary “Wayak” to offer data-driven healthcare services, utilising data analytics and artificial intelligence to capitalise on IDH’s database of over c.13 million patients



Wayak Services



Medication to be hand-delivered directly to the patient



Service provider referrals to IDH’s network



Online consultations with Diagnostics reminders



Discounted services at IDH’s network of service providers, including but not limited to lab tests



Customer service and follow-up through our call center



Healthcare Records by patients’ request

Growing Geographic Footprint— Investment Rationale

IDH's regional expansion strategy targets acquisitions in African, Middle Eastern and Asian markets where it can deploy its proven business model and generate accretive value



Growing economies and strong demographics



Similar healthcare market structure to IDH's existing markets – no general practitioner and consumer-facing



Countries with stable regulatory environment




Acquisition targets must have been profitable for at least two to three years



Well-run companies with qualified management team able to deliver on strategy



Targeting majority stakes




* Operations in Saudi Arabia are set to commence in September 2023

Growing Geographic Footprint – Nigeria Expansion

In December 2017, IDH further expanded its geographical footprint with an investment in Nigeria, a value-accretive acquisition in a large, fragmented and underpenetrated diagnostic services market where our business model is well-suited to capitalise on similar healthcare and consumer trends. **The Group's Nigerian operations saw EBITDA losses narrowed significantly to EGP 7 million in FY 2021 on the back of strong revenue growth for the year. EBITDA losses have temporarily widened in FY 2022 and Q1 2023, driven primarily by high levels of inflation (particularly increases in diesel prices).**

IDH entered into a strategic alliance with Man Capital LLP to form Dynasty Holding Group (“Dynasty”), which in turn partnered with the International Finance Corporation to acquire a majority stake in Eagle Eye Echo-Scan Limited (“Echo-Scan”), a medical diagnostics business based in Nigeria. The acquisition was financed through a capital increase.



Patient Split



Key player in Nigeria, providing quality medical diagnostic services across 12 state-of-the-art diagnostic centres in country's underserved private healthcare sector

Locations

USD 25 million will be collectively invested into Echo-Lab to expand its service offering, nationwide footprint, and improve its quality standards

USD **9.2** mn

Invested by Dynasty in
FY2018 + FY2019

USD **2.5** mn

Invested by Dynasty in
FY2020 + FY2023

USD **11.7** mn

Invested by Dynasty to
Date

USD **1.1** mn

Invested by IFC in FY2018

USD **1.0** mn

Invested by IFC in FY2019

USD **2.1** mn

Invested by IFC to Date

Nigeria Branch Roll-Out and Renovations

Opebi Branch Renovation and Rebranding




Area 11 Branch Renovation and Rebranding



Benin Branch Renovation & Rebranding



New Victoria Island Branch




Growing Geographic Footprint – KSA Expansion

In October 2022, IDH and Biolab signed a joint venture agreement with Izhoor, a company owned by Fawaz Alhokair, to launch a full-fledged pathology diagnostic services provider in Saudi Arabia

Deal Structure

The new joint venture will be owned 50% by IDH Group (30% controlled by IDH and 20% controlled by Biolab), with the remaining 50% owned by Izhoor. Over the coming four years, total investments in the venture are set to reach USD 19.7 million.



Deal Specifics

USD **19.7** mn

Estimated investment cost
(SAR 73.7 mn)

USD **2.8** mn

IDH equity investment

USD **1.9** mn

Biolab equity investment

Sep. 2023

First branch launch date

8 BoD members

4 members from IDH Group
4 members from Izhoor

3

Executive committee
members 2 from IDH and 1
from Izhoor

An Attractive Market

14.4%

Share of govt. budget on
healthcare (60% of GCC
total)

300/2,250

Hospitals/Healthcare
Centres privatised by 2030

2%

Avg. population growth rate
(3rd largest in the region)

**Attractive Diagnostic
Market Growth Profile**

One of the fastest growing
in the Middle East and
Africa (MEA) over the
coming six years

**High Healthcare
Spending per Capita**

Set to rise further in the
coming years

2030 Vision

Healthcare and private
sector participation are key
areas of focus for the Saudi
government

Strong Leadership & Governance



Governance

A World-Class Board of Directors

The majority of members of IDH's Board of Directors are independent and offer significant experience in the healthcare market, MENA region and investment activities



Lord St John of Bletso¹

Independent Non-Executive Chairman
Chairman of the Nomination Committee

Lord St John has been an active Crossbench member of the House of Lords, UK Parliament, since 1978. He serves on the boards of several listed and unlisted companies, including Yellow Cake plc, Smithson Investment Trust plc, Gulf Marine Services plc, Strand Hanson Ltd, and Airport Holdings Mauritius. He also holds mentoring advisory roles with Farrant Group Ltd., Qredo Ltd., BetWay Ltd., Geobear Ltd, and ROC Technologies Ltd. Lord St John has a strong interest in the charitable sector and serves as a trustee to several charities focused on wildlife conservation, poverty reduction, education, and healthcare. He graduated with BA Law and BSocSc Psychology from Cape Town University, a BProc i from the University of South Africa, and a Master of law LLM from the London School of Economics. He practised as an attorney before his 25-year career in financial services in the City in London.



Prof. Dr. Hend El Sherbini

Group Chief Executive Officer

Dr. Hend El Sherbini has been IDH Group's Chief Executive Officer since 2012, and prior to that, she served as the CEO of Al Mokhtabar — Egypt's oldest diagnostic services brand — between 2004 and 2012. She received her MBBCh and her Master's degree in Clinical and Chemical Pathology from Cairo University in the early 1990s. She also holds a Master's degree in Public Health from Emory University in Atlanta. Dr. El Sherbini obtained her PhD in Immunology from Cairo University in 2000, where she is also a professor of clinical pathology at the university's Faculty of Medicine. She sits on the Board of the American Society of Clinical Pathology (Egypt) and consults on the international certification process. Dr. El Sherbini completed an Executive MBA from the London Business School in 2015 and was featured as one of Forbes' most powerful women between 2016 and 2023.



Hussein Choucri^{1,2,3}

Independent Non-Executive Chairman of the Remuneration Committee

Mr. Choucri is Chairman and Managing Director of HC Securities and Investment, which he established in May 1996. He currently sits on the boards of EDITA Food Industries S.A.E, Fawry Banking and Payment Technology Services Ltd. (Fawry), and Integrated Diagnostic Holdings (IDH). Mr. Choucri served as a Managing Director of Morgan Stanley from 1987 to 1993 and served as Advisory Director at Morgan Stanley from 1993 to 2007. He received his Management Diploma from the American University in Cairo (AUC) in 1978.



Dan Olsson^{1,2,3}

Independent Non-Executive Chairman of the Audit Committee

Mr. Olsson has long and extensive international experience in the diagnostic and healthcare services sector, where he has served in a range of executive positions. Among others, he served as head of diagnostics in the pan-European healthcare group Capio; CEO of Unilabs, a pan-European diagnostic provider; CEO of Helsa, a Swedish healthcare group; as well as CEO of Team Olivia Group, a Nordic care services group. He currently works as an independent advisor and holds non-executive positions at Purch AB, Batten AB, and Ambea AB (Publ). Mr. Olsson has worked in the healthcare sector since 1999. Mr. Olsson studied Economics at the University of Lund in Sweden.



Richard Henry Phillips

Non-Executive Director

Mr. Phillips is a founding partner of Actis LLP, the emerging markets private equity group. As Actis LLP is one of the Company's major shareholders, Mr. Phillips is not considered by the Board as being independent. He is the Head of Private Equity for Actis and is a member of the Actis Investment Committee. Mr. Phillips is a director on the board of a number of companies, including Honoris Holding Limited, Les Laboratoires Medis SA, and others. Mr. Phillips holds a degree in Economics from the University of Exeter.



Yvonne Stillhart^{2,3}

Non-Executive Director

Ms. Yvonne Stillhart has over 30 years of experience as a successful Senior Executive leader and business founder working with growth-driven companies across broad industries and geographical regions in Emerging Markets, USA, Europe, and Sub-Saharan Africa. She has been a non-Executive Director and Audit Committee member for the last 12 years, and she currently serves as an independent non-executive member of the board and audit and risk committee of UBS Asset Management Switzerland AG, and as a non-executive director and member of the audit committee of abrdn Private Equity Opportunities Trust Plc. Ms. Stillhart is also the Chairperson and member of the Social and Ethics Committee of the South African listed EPE Capital Ltd. She holds a Directors Certificate from Harvard Business School and is a Qualified Risk Director from the DCRO Institute. She also holds the ESG Competent Boards Certificate and is fluent in German, English, Spanish, and French.

¹ Nomination Committee, ² Remuneration Committee, ³ Audit Committee

Governance

IDH is committed to implementing best practices in corporate governance through the expertise of both the individual Directors and outside parties

Anti-Bribery and Anti Corruption Policy (ABAC)

The IDH Anti-Bribery and Corruption Policy requires compliance with the highest ethical standards and all anti-corruption laws applicable in the countries in which IDH conducts business (whether through a third party or otherwise).

No Referral Fee Policy

The practice of paying kickbacks is incompatible with the laws of most established international jurisdictions. IDH maintains a strict policy on referral fees and prohibits the payment of “commissions and financial incentives or making illegal profits” when referring patients for medical tests.

Gift Policy

IDH is committed to serving our customers and working with our partners with the highest standards of integrity. In line with this commitment, we adopt a “No Gift Policy” whereby our employees are not allowed to exchange gifts with current or potential customers, suppliers or business partners. This is to prevent any conflicts of interest, or appearance of such in our business dealings.

Internal Audit Procedures

The Board has delegated oversight of the Group’s system of internal controls to the Audit Committee to safeguard the assets of the Group and the interests of shareholders.

The Audit Committee reviews the effectiveness of the Group’s internal controls on an ongoing basis and reports back to the Board with their findings and recommendations.

The Board has accordingly established that the Group has in place internal controls to manage risk including:

the outsourcing of the internal audit function to professionals from Ernst & Young (EY) until an Internal Auditor was appointed for the Group on 16 May 2016;

the identification and management of risk at the level of operating departments by the heads of those departments; and

regular Board level discussion of the major business risks of the Group, together with measures being taken to contain and mitigate those risks.

While not required to comply with UK Corporate Governance Code, IDH aims to voluntarily comply with aspects of the Code while continually working toward closing the gap with premium listed entities on the London Stock Exchange. To date, the Company has established four Board committees (members on overleaf):

1 **Nominations Committee**

2 **Remuneration Committee**

3 **Audit Committee**

4 **M&A Committee**

Sustainability

Founded on the principle of providing quality medical assistance and services to better the lives of individuals and the community at large, IDH views corporate responsibility initiatives as an extension of its core purpose with the aim of improving communities in which it does business

The Moamena Kamel Foundation for Training and Skill Development

Primary Services

1

Free healthcare clinics

2

Loans for entrepreneurial women

3

Educational services for the children of Al Duweiga community

4

Providing food for families in need of such assistance

5

Coverage of running costs for the ICU at Cairo's public-sector Kasr El Aini Hospital

IDH commits up to 1% of the net after-tax profit of its subsidiaries, Al Borg and Al Mokhtabar, to the Moamena Kamel Foundation for Training and Skill Development.

Other Corporate Responsibility Initiatives


- Services to Kasr El Aini Hospital
 - Providing medical supplies to ICU and other units
 - Providing monthly incentives for nurses at the ICU
 - Provided 12-20 beds
- Providing finance and in-kind support to El Manial Hospital
- Financial and in-kind support to Egyptians during natural disasters
- Providing Ramadan iftar (feast) meals to the underprivileged during Ramadan
- Providing free medical tests to underprivileged Egyptian children
- Sponsoring medical convoys in Fayoum

Appendix



IDH Development Story


Over 40 years of industry experience, complemented by strategic expansion to develop a strong market position across products and geographies. Today IDH has built a **scalable platform that is positioned for further strong growth**



Source: Company data

IDH Development Story

Over 40 years of industry experience, complemented by strategic expansion to develop a strong market position across products and geographies. Today IDH has built a **scalable platform that is positioned for further strong growth**



Source: Company data

